PubMed Health⌕ Search

Biomedical subjects

C Baur

Publications and source records attributed to C Baur.

At least 55 records · Page 3Linked to original sources
PubMed1986

The quinolones in chronic bronchitis.

Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients). In general, good clinical results were observed in 50-70% of the patients treated, most failures being due to relapses or reinfections with Streptococcus pneumoniae or Pseudomonas aeruginosa. Studies on blood and sputum concentration suggested that gastro-intestinal absorption was not always satisfactory. Unwanted drug effects were noted with all agents studied, generally presenting as stomach pain, nausea, hallucinations, or dizziness. Most adverse drug reactions were seen with enoxacin, often but not always during concomitant treatment with theophylline.

Adult↗
PubMed1986

[New oral quinolone compounds in chronic bronchitis].

Clinical, microbiological and pharmacokinetic results are presented from studies in 186 patients treated with the new quinolone antimicrobial agents enoxacin, pefloxacin, ciprofloxacin or ofloxacin. Almost all had been admitted to hospital for acute purulent exacerbations of chronic bronchitis, associated mainly with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa. The H. influenzae and B. catarrhalis strains were generally very sensitive to the quinolones and sputum concentrations of 1.3 to 4.5 mg/l exceeded the MICs (geometric mean values 0.07 to 0.44 mg/l) by a factor of more than 10. In contrast, P. aeruginosa was slightly less sensitive (geometric mean MICs 0.4 to 4.4 mg/l) and S. pneumoniae much less so (with geometric mean MICs between 0.84 and 6.7 mg/l) and a number of treatment failures were noted with these organisms. Various unwanted drug effects (mostly upper gastro-intestinal) were seen, particularly with enoxacin. The best clinical results were observed with ofloxacin, even with once daily dosage, but the results with the other quinolones could only be described as moderate.

Administration, Oral↗
PubMed1986

Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.

Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin. The patients were divided into four groups of 20 patients each and administered either 500 mg, 750 mg (two different batches of tablets) or 1000 mg twice daily for ten days. Most of the patients with Haemophilus influenzae and Branhamella catarrhalis infections were treated successfully but the results in patients with Streptococcus pneumoniae and Pseudomonas aeruginosa infections were less satisfactory. Although the ciprofloxacin MICs for the latter organisms were relatively low, mean serum and sputum concentrations measured on the first day of treatment did not exceed 2-3 mg/l and 1-2.3 mg/l respectively. The overall clinical results for all dosage regimes were only fair, mainly due to failure to eradicate Streptococcus pneumoniae and Pseudomonas aeruginosa. Adverse effects (nausea, stomach pain or hallucinations) were seen in eight patients, causing treatment to be discontinued in five. It is concluded that ciprofloxacin is only of limited use in the treatment of respiratory tract infections unless Streptococcus pneumoniae is absent.

Aged↗
PubMed1986

Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease.

Thirty hospital patients with acute purulent exacerbations of chronic respiratory disease were treated with 400 mg ofloxacin by mouth either once or twice daily for ten days. Studies on concomitantly administered theophylline showed no significant accumulation. Most sputum cultures no longer yielded pathogens at the end-of-treatment, but some Pseudomonas aeruginosa strains persisted. Clinical results were usually excellent at the end of treatment (26/30 patients) and excellent or good a week later (24/30), although they were better in the patients receiving once daily dosage. One patient developed a maculopapular drug rash which disappeared when ofloxacin was discontinued.

Adult↗
PubMed1986

Chordoma of the thorax.

Chordomata are malignant tumours which arise from foetal notochordal rests. They occur alongside the vertebral column, mostly at the cranial or caudal extremities, but they are seldom found in the thorax. A description is given of a thoracic chordoma in a 70-year-old male patient who presented with difficulty in swallowing and breathing. Emphasis is placed on the role of computer-assisted tomography in reaching the diagnosis.

Aged↗
PubMed1981

[Neutralizing capacity, pepsin inactivation and binding to bile acids and lysolecithin of the antacid magaldrate (author's transl)].

The neutralizing capacity of pentaaluminum-decamagnesiumhentriacontahydroxide-bis(sulfate)-hydrate (magaldrate, Riopan), a stable Al-Mg-hydroxide mono-substance, determined by a modification of the method described in literature, surpasses the efficacy index (mval divided by g) of various commercial antacids. These results coincide with the findings of other workers. The intragastric pH is rapidly and consistently raised to a value between 3 and 5 which is not exceeded (no acid rebound). Due to this fact, pepsin is inactivated and finally adsorbed by magaldrate. Moreover, magaldrate binds a considerable amount of substances contained in duodeno-gastric reflux, such as bile acids and lysolecithin (aggressors in case of gastritis, peptic ulcer, stress ulcer, peptic esophagitis).

Aluminum Hydroxide↗